CN104664407B - A kind of nutrient with noise immunity hearing loss - Google Patents
A kind of nutrient with noise immunity hearing loss Download PDFInfo
- Publication number
- CN104664407B CN104664407B CN201510137493.8A CN201510137493A CN104664407B CN 104664407 B CN104664407 B CN 104664407B CN 201510137493 A CN201510137493 A CN 201510137493A CN 104664407 B CN104664407 B CN 104664407B
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- nutrient
- hearing loss
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 49
- 206010011878 Deafness Diseases 0.000 title claims abstract description 21
- 230000010370 hearing loss Effects 0.000 title claims abstract description 21
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 21
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 21
- 230000036039 immunity Effects 0.000 title claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- 229940088594 vitamin Drugs 0.000 claims abstract description 26
- 229930003231 vitamin Natural products 0.000 claims abstract description 26
- 235000013343 vitamin Nutrition 0.000 claims abstract description 26
- 239000011782 vitamin Substances 0.000 claims abstract description 26
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 22
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims abstract description 18
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 15
- 239000011718 vitamin C Substances 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000011777 magnesium Substances 0.000 claims abstract description 13
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 12
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 12
- 239000011719 vitamin A Substances 0.000 claims abstract description 12
- 229940045997 vitamin a Drugs 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940087168 alpha tocopherol Drugs 0.000 claims abstract description 5
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 5
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 5
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229940091250 magnesium supplement Drugs 0.000 claims description 12
- -1 Special-shaped sheet Substances 0.000 claims description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims description 11
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 11
- 235000019163 vitamin B12 Nutrition 0.000 claims description 11
- 239000011715 vitamin B12 Substances 0.000 claims description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 229960003495 thiamine Drugs 0.000 claims description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims description 8
- 239000011691 vitamin B1 Substances 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 7
- 239000001755 magnesium gluconate Substances 0.000 claims description 7
- 229960003035 magnesium gluconate Drugs 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000007938 effervescent tablet Substances 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 6
- 229960000342 retinol acetate Drugs 0.000 claims description 6
- 235000019173 retinyl acetate Nutrition 0.000 claims description 6
- 239000011770 retinyl acetate Substances 0.000 claims description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000007968 orange flavor Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 125000001020 α-tocopherol group Chemical group 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 abstract description 19
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 16
- 230000006378 damage Effects 0.000 abstract description 15
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 230000035764 nutrition Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 231100000734 genotoxic potential Toxicity 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002768 hair cell Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 210000003027 ear inner Anatomy 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 229940033282 vitamin b6 2 mg Drugs 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003477 cochlea Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000012076 audiometry Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 210000001595 mastoid Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 229940126707 lipid peroxidation inhibitor Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229950008558 ulinastatin Drugs 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of nutrient with noise immunity hearing loss, it is made up of following raw materials by weight：600 1000 parts of N acetyl L cysteine, 14 parts of vitamin A, 15 parts of vitamin B1,15 parts of vitamin B2,1 10 parts of vitamin B6,0.01 0.05 parts of vitamin B12,60 1000 parts of vitamin C, Vitamin E in terms of alpha tocopherol 15 300 parts, 50 400 parts of magnesium and 79 3175 parts of the acceptable adjuvant of food.Experimental data shows, nutrient of the present invention has the prevention effect of highly significant to noise induced hearing loss.Nutrient of the present invention can enhancing body oxidation resistance damage with mitigating exitotoxicity, there is evident in efficacy, low genotoxic potential, cheap it is adaptable to living for a long time, working in the protection of the noise induced hearing loss of crowd that lasting high intensity noise exposes etc. in environment and daily nutrition element supplements.
Description
Technical field
The present invention relates to a kind of composite nutrient, more particularly to one kind are used for vitimin supplement, mineral, there is preventing and treating
Noise induced hearing loss acts on, and the nutrient playing a role in health care belongs to compositionss preparing technical field.
Background technology
With the development of modern industry and weaponry, the harm of noise is increasingly serious, and is embodied in many aspects, makes an uproar
Sound can cause dysfunction or even the pathology damage of the audition external system such as acoustic trauma and nerve, cardiovascular, digestion or organ.
Noise is the hazard factor of army's working environment generally existing, the above relevant mark of noise intensity of my army's major part weaponry
The limit value of quasi- regulation.The incidence rate of exposed personnel acoustic trauma is high, has a strong impact on work efficiency, health and fighting capacity, especially in information
Change in war, gently then affect work, heavy then bungle the chance of winning a battle.
The main target organ of noise induced damage is organon audituss, and noise induced hearing loss is mainly shown as under auditory sensitivity
Fall, the threshold of audibility raises, and language accepts and signal distinguishing ability reduces, and this process is the process that physiology travels to pathology, causes pathology
Damage and have to reach certain noise intensity and (or) time of contact.Noise to the intensity of the harm of auditory system and noise,
The factors such as frequency, open-assembly time and individual sensitivity are relevant, there is dosage within the specific limits between noise exposure and hearing loss
Effect relation.It is all to damage internal ear Sensory hair cell by mechanicalness or metaolic that noise causes the mechanism of acoustic trauma.
Noise can cause to cochlea most cells to damage, and wherein stand in the breach most is outer hair cell.It is now thought that exitotoxicity draws
The oxidativestress damage sent out is that Acoustic exposure leads to the main trigger mechanism of Hair Cell Death in cellular level.In addition, noise also may be used
Hinder human body to the absorption of various vitamin and utilization, and accelerate the excretion to water soluble vitamins for the human body, this is likely to into one
Step reduces body normal physiological function, increased and damages the risk occurring.
The medicine for the treatment of sound-induced auditory damage mainly has vasodilation class, neurotrophy class, blood dilatation class, Chinese medicine to live at present
Blood silt class etc., but effect is all undesirable.Noise induced hearing loss focuses on prevention, and oxidative damage and exitotoxicity are in hair cell generation
Thanking property plays very important effect in damaging, and improves cochlea endogenous anti-oxidative level or external supply antioxidant is permissible
Mitigate damage of hair cell and hearing loss.Propyloxy phenyl base glycosides (PIA) can improve perilymph GSH-PX activity and SOD level,
Enhance cochlea oxidation resistance, effectively reduce noise induced hearing loss and wool Se content；Allopurinol, polyethylene second two
Alcohol, Mannitol, N-acetylcystein, acetyl-L-carnitine, salicylate etc. by oxygen radical removing or suppress its product
Raw, also can effectively prevent and treat noise induced hearing loss, lipid peroxidation inhibitor and ulinastatin, alpha-lipoic acid, Semen Ginkgo polysaccharide
Also it is proved effectively Deng antioxidant.In addition, regulation of calcium agent MK801, nimodipine etc. can be by improving exitotoxicity
The calcium ion disbalance causing, and then play the effect of preventing and treating noise induced hearing loss.
Because most of noise exposure crowd is Occupational Exposure, it is exposed to the noise ring exceeding relevant criterion for a long time
Border, such as adopts chemoprophylaxiss for such crowd, then needs Long-term taking medicine, may produce toxic and side effects to body.It is desirable to
While extra-nutrition material, it is obtained in that the multi-effects such as prevention noise induced hearing loss, opposing oxidative damage.Therefore,
On the basis of ordinary nutritional agent, strengthening has the active component of anti-exitotoxicity, anti-oxidation function, for occupational noise exposure
The nutrient that the Long term prophylatic of crowd is taken is it is contemplated that the effect of good preventing and treating noise induced hearing loss will be received.
Content of the invention
The defect existing for prior art, the present invention provides a kind of nutrient with noise immunity hearing loss, warp
Cross lot of experiments, choose compound vitamin, mineral and glutathione precursor material and combined with special ratios, obtain
Good antioxidation, anti-exitotoxicity, improve internal ear aerobic metabolism and energy generation and other effects.Before its reason is Glutathione
Body material ACETYLCYSTEINE (NAC) and vitamin A, B race, C, E can work in coordination with performance anti oxidative damage, and
Magnesium then can block the cell Ca2+ influx of exitotoxicity initiation, reduces the damage of hair cell leading to because of calcium overload.Nutrition of the present invention
Agent is lived be applied to for a long time, the supplement of the daily nutrition of the crowd working in the noise circumstance with potential hazard element, in case
Control noise induced hearing loss.
In order to solve above-mentioned technical problem, the nutrient with noise immunity hearing loss proposed by the present invention, by weight
Number is made up of following raw materials：N-acetyl-L-cysteine 600-1000 part, vitamin A 1-4 part, -5 parts of VB11, dimension
Raw element B21-5 part, vitamin B6 1-10 part, vitamin B12 0.01-0.05 part, vitamin C 60-1000 part, Vitamin E and with
Alpha-tocopherol meter 15-300 part, magnesium 50-400 part and food acceptable adjuvant 79-3175 part.
Preferably：900 parts of described N-acetyl-L-cysteine, 3 parts of vitamin A, vitamin B12 .5 part, vitamin
B22.5 part, 2 parts of vitamin B6,0.01 part of vitamin B12,500 parts of vitamin C, Vitamin E in terms of alpha-tocopherol 270 parts,
300 parts of magnesium and the acceptable adjuvant of food.
ACETYLCYSTEINE (NAC) is the acetyl derivatives of essential amino acid L-Cysteine, can lead to
Cross a free sulfhydryl group (- SH of nucleophilic) directly having an effect with electrophilic oxide group and play direct antioxygen and be turned into
With.NAC can protect α -1 antitrypsin (elastase inhibitor) to inactivate from hypochlorous effect.The molecule knot of NAC
Structure renders it susceptible to pass through cell membrane, in the cell NAC deacetylate, forms L-Cysteine, and this is a kind of synthesis gluathione
The essential amino acids of peptide (GSH).GSH is a kind of highly active tripeptides being widely present in various animal tissues.Glutathione is
Intracellular most important protective agent, plays a significant role to the integrity keeping cell function and cellular morphology, still prevents thin
The oxygen-derived free radicals from inside and outside for the born of the same parents and the infringement of various cytotoxic substance.NAC plays at the suitable horizontal aspect of GSH of holding
Important function, thus contribute to the cytotoxin infringement protecting cell not lead to because internal GSH level is too low.Research shows,
NAC can effectively prevent and treat noise induced hearing loss (the .J Am Acad Audiol such as Kramer S., 2006,17:265–278).Can
By commercially available acquisition ACETYLCYSTEINE.
Vitamin A is a kind of fatsoluble vitamin playing important physiological function in body.It is except maintaining machine
Outside the functions such as the Growth and Differentiation of body normal vision and epithelium, free radical can also be caught, be quenched single line oxygen (1O2), improve body and resist
Oxidation protection capability.Vitamin A deficiency incidence rate is higher, but if a large amount of absorption has overt toxicity to body again, therefore, dimension life
The absorption of plain A should control in zone of reasonableness.Vitamin A in the present invention can be by adding Vitamin A Acetate and/or dimension life
Plain A cetylate obtains, preferred vitamin A cetylate.
Vitamin B1 participates in the oxidative deamination reaction of 2-ketoacid and the transketolase reaction of phosphopentose pathway in vivo,
Energy metabolism aspect plays a significant role.People continuous work 4 hours in the noise of 85-100 decibel intensity, internal vitamin
B1 will reduce about 30%.
Vitamin B2 is catalyzed extensive oxidation-reduction reaction in vivo, also has antioxidant activity, is to promote energy in body
Amount generates the important substance with anti-lipid peroxidation.Noise exposure can significantly reduce the level of body vitamin B2.
Vitamin B6 participates in nearly hundred kinds of mainly relevant with amino acid metabolism in vivo enzyme reactions, also can affect vestibular function
Stability.Noise exposure can significantly reduce the level of vitamin B6.
Vitamin B12 and protein synthesis and cell form closely related, also have with odd numbers of carbon atoms fat metabolic process
Close.Noise exposure can significantly reduce the level of vitamin B12.
Vitamin C is a kind of electron donor, can carry out reversible oxidation in vivo, can remove multiple freedom as antioxidant
Base, participates in multiple important biosynthetic processes as coenzyme.Appropriate vitimin supplement C is conducive to body to maintain higher antioxygen
Change level.
Vitamin E is important high-efficiency antioxidant agent in non-enzymatic antioxidant system, protects cells from free radical in vivo
Infringement, improves immunologic function, delaying cell aging degenerative process.People's continuous work 4 in the noise of 85-100 decibel intensity is little
When, internal vitamin C will reduce about 40%.Vitamin E in the present invention can by add Vitamin E acetate and/or
Vitamin e succinate obtains, preferred vitamin E acetate.
Magnesium is the dominant cation in human body cell, is concentrated in mitochondrion, is only second to potassium and phosphorus, only secondary in extracellular fluid
Occupy the 3rd in sodium and calcium, be the required material of the basic biochemical reaction of internal various kinds of cell.Magnesium can affect potassium ion and calcium from
The transhipment of son, the transmission of adjustment signal, participate in the synthesis of energy metabolism, protein and nucleic acid；The activation of catalyzing enzyme and suppression and
The regulation and control of cell cycle, cell proliferation and cell differentiation；Magnesium also participates in anti-body oxidative stress process.Noise exposure can cause
Internal ear glutamic acid and its NMDA type glutamate receptor abnormal activation, a large amount of flow of calcium ions cause intracellular calcium overload, cause cell
Damage, i.e. exitotoxicity.Magnesium ion can block calcium channel, mitigates the exitotoxicity damage that intracellular calcium overload causes.This
In bright, content of magnesium can be obtained by adding organic magnesium salts, and described organic magnesium salts can be magnesium gluconate, magnesium lactate, citric acid
The edible magnesium salt such as U.S., preferably magnesium gluconate.
Nutrient of the present invention can adopt one of following dosage forms：Hard capsule, soft capsule, ordinary tablet, coated tablet, thin
Film garment piece, Special-shaped sheet, chewable tablet, effervescent tablet, dispersible tablet, granule, pill, solution, syrup.It is preferably tablet or capsule
Agent.
The edible adjuvant of various routines also can be added, this adjuvant is according to nutrient in the formula of nutrient of the present invention
Determining, the dosage form of nutrient is tablet to dosage form difference, and described edible adjuvant includes 100 parts of Lactose, 80 parts of Microcrystalline Cellulose, carboxylic
40 parts of methyl starch sodium and 5 parts of magnesium stearate；The dosage form of nutrient is effervescent tablet, and described edible adjuvant includes citric acid 1000
Part, 500 parts of malic acid, 1400 parts of sodium bicarbonate, 35 parts of aspartame, 60 parts of orange flavor, 60 parts of sodium chloride and
PEG6000120 part；The dosage form of nutrient is hard capsule：Described edible adjuvant includes 15 parts of Hypromellose, hydroxypropyl first fibre
15 parts of dimension element, 45 parts of carboxymethyl starch sodium and 4 parts of magnesium stearate.
The experiment proved that, the nutrient that the present invention provides has the effect of good noise immunity hearing loss.The present invention
There is advantages below：
1) the different molecular approach being occurred according to noise induced hearing loss, using small molecule amino acid derivativges, vitamin
With the reasonable combination of mineral, respectively from antioxidation, anti-exitotoxicity, improve in terms of internal ear aerobic metabolism and energy generate etc.
Row is intervened so that having synergistic function between each nutrient, and the effect is significant of preventing and treating noise induced hearing loss strengthens.
2) this nutrient comprehensive nutrition, also by its high-efficiency antioxidant efficiency and then can improve resisting stress capability, fit
Supplement for the daily nutrition element of occupational noise exposure person particularly military noise operating personnel.
3) ingredient origin enriches, and toxic and side effects are extremely low, suitable professional population long-term taking, safe ready.
Specific embodiment
With reference to subordinate list and specific embodiment, technical solution of the present invention is described in further detail, described is concrete
Embodiment only explains to the present invention, not in order to limit the present invention.
If nutrient group component of the present invention is daily dose, wherein all number dosage are all in terms of milligram, additionally, daily dose
One or more dosage units can be comprised.
Embodiment 1, there is the nutrition agent prescription of noise immunity hearing loss.
The present embodiment 1 provides each active component in compound vitamin in the present invention, mineral, amino acid derivativges nutrient
Daily dose, this dosage once can take as a dosage unit or multiple dosage unit part vic in a day.
The formula of embodiment 1 nutrient is as shown in table 1：
The raw material of table 1 embodiment 1 composite nutrient and each active component formula
| Nutrient title | Raw material | Dosage | Active component content |
| N-acetylcystein | N-acetyl-L-cysteine | 900mg | 900mg |
| Vitamin A | Vitamin A Acetate Powder | 19.88mg | 3000μgRE |
| Vitamin B1 | Vitamin B1 | 2.5mg | 2.5mg |
| Vitamin B2 | Vitamin B2 | 2.5mg | 2.5mg |
| Vitamin B6 | Vitamin B6 | 2mg | 2mg |
| Vitamin B12 | Vitamin B12 | 10mcg | 10mcg |
| Vitamin C | Vitamin C | 500mg | 500mg |
| Vitamin E | Vitamin E acetate | 540mg | 270mg |
| Magnesium | Magnesium gluconate | 5.2g | 300mg |
In table 1, " RE " refers to retinol equivalent, represents all and has retinol active substance (the established vitamin A of inclusion
And provitamin A) total amount (μ g).
Embodiment 2, have noise immunity hearing loss nutrient piece preparation, raw material and dosage as shown in table 2：
The component of table 2. embodiment 2 nutrient piece and dosage
| Raw material | Dosage |
| N-acetyl-L-cysteine | 900mg |
| Vitamin A Acetate Powder | 19.88mg |
| Vitamin B1 | 2.5mg |
| Vitamin B2 | 2.5mg |
| Vitamin B6 | 2mg |
| Vitamin B12 | 10mcg |
| Vitamin C | 500mg |
| Vitamin E acetate | 540mg |
| Magnesium gluconate | 5.2g |
| Adjuvant | Dosage |
| Lactose | 100mg |
| Microcrystalline Cellulose | 80mg |
| Carboxymethyl starch sodium | 40mg |
| Magnesium stearate | 5mg |
Preparation method：Weigh raw material by above-mentioned formula dosage, according to equal increments method mixing, then with Lactose, microcrystalline cellulose
Element, Sodium Hydroxymethyl Stalcses and the acceptable auxiliary materials and mixing of magnesium stearate food, the mix powder direct compression that will prepare, both
?.Described tablet can be obtained Film coated tablets by coating further.
Embodiment 3, have noise immunity hearing loss nutrient hard capsule preparation, raw material and dosage as shown in table 3：
The component of table 3. embodiment 3 nutrient hard capsule and dosage
| Raw material | Dosage |
| N-acetyl-L-cysteine | 900mg |
| Vitamin A Acetate Powder | 19.88mg |
| Vitamin B1 | 2.5mg |
| Vitamin B2 | 2.5mg |
| Vitamin B6 | 2mg |
| Vitamin B12 | 10mcg |
| Vitamin C | 500mg |
| Vitamin E acetate | 540mg |
| Magnesium gluconate | 5.2g |
| Adjuvant | Dosage |
| Hypromellose | 15mg |
| Carboxymethyl starch sodium | 45mg |
| Magnesium stearate | 4mg |
Preparation method：Weigh raw material by above-mentioned formula dosage, according to equal increments method mixing, then with carboxymethyl starch sodium and
The acceptable auxiliary materials and mixing of the food such as Hypromellose, mixture carries out non-slurry pelletizing, adds magnesium stearate, loads capsule,
Both obtained hard capsule.
Embodiment 4, have noise immunity hearing loss nutrition effervescent tablet preparation, raw material and dosage as shown in table 4：
The component of table 4. embodiment 4 nutrition effervescent tablet and dosage
| Raw material | Dosage |
| N-acetyl-L-cysteine | 900mg |
| Vitamin A Acetate Powder | 19.88mg |
| Vitamin B1 | 2.5mg |
| Vitamin B2 | 2.5mg |
| Vitamin B6 | 2mg |
| Vitamin B12 | 10mcg |
| Vitamin C | 500mg |
| Vitamin E acetate | 540mg |
| Magnesium gluconate | 5.2g |
| Adjuvant | Dosage |
| Citric acid | 1000mg |
| Malic acid | 500mg |
| Sodium bicarbonate | 1400mg |
| Aspartame | 35mg |
| Orange flavor | 60mg |
| Sodium chloride | 60mg |
| PEG6000 | 120mg |
Preparation method：Weigh raw material by above-mentioned formula dosage, according to equal increments method mixing, then with citric acid, malic acid,
The acceptable auxiliary materials and mixing of the food such as sodium bicarbonate, aspartame, orange flavor, sodium chloride and PEG6000, mixture is suitable
Carry out direct powder compression under humidity, both obtain effervescent tablet.
Experimental example, nutrient of the present invention preventing and treating noise induced hearing loss Function detection, following invention process is only sketched at this
Has the experiment content of significance in invention.
Animal packet and process：Healthy adult pattern Cavia porcelluss 29 (female 14, male 15), weight 230～
280g, is provided by Hygiene ＆ Environmental Medical Science Inst., Academy of Military Medical Scien's Experimental Animal Center.
Animal is observed 3 days before experiment, is randomly divided into 4 groups, wherein：
Experimental comparison group, totally 6 healthy adult pattern Cavia porcelluss, female, male each 3；Experimental comparison group gives deionized water.
1 group of nutrient, totally 8 healthy adult pattern Cavia porcelluss, female, male each 4；Give compound vitamin (vitamin
A300 μ gRE/kg/ day+vitaminB10 .25mg/kg/ day+vitamin B2 0.25mg/kg/ day+vitamin B6 0.2mg/kg/ day+
Vitamin B12 1mcg/kg/ day+vitamin C 50mg/kg/ day+vitamin E2 7mg/kg/ day)+N-acetyl-L-cysteine
(400mg/kg/ day).Each component is dissolved in deionized water, is configured to 500mg/100ml suspension, administration by gavage is administered.
2 groups of nutrient, totally 7 healthy adult pattern Cavia porcelluss, female 3, male 4；Give compound vitamin (ibid)+
Magnesium (200mg/kg/ day).Each component is dissolved in deionized water, is configured to 500mg/100ml suspension, administration by gavage is administered.
3 groups of nutrient, totally 8 healthy adult pattern Cavia porcelluss, female, male each 4；Give compound vitamin (ibid)+N-
Acetyl-L-Cysteine (400mg/kg/ day)+magnesium (200mg/kg/ day).Each component is dissolved in deionized water, is configured to
500mg/100ml suspension, administration by gavage is administered.
Expose first three sky until whole at the end of experiment in the 7th day after exposing be administered.
Laboratory animal noise exposure：All tested Cavia porcelluss are placed in wire mesh cage, are put in ground by same radius, upper hovering
Hang speaker.White noise is sent by B＆K 3560C signal generating system (B＆K company, Denmark), is connected in through power amplifier and raises one's voice
Device.By B＆K2209 type precision sound level meter (B＆K company, Denmark) Monitoring and Controlling, the noise exposure sound intensity is (110.0 ± 1) dB
(SPL), daily expose 3h, continuous 2 days.
Tb-ABR detects pure tone audiometry：Before noise exposure and 0 day after noise exposure, 1 day, 3 days, 7 days difference Fundamentals of Measurement
Threshold of audibility situation of change after value and noise exposure, measuring method：3 needle electrodes are inserted Cavia porcelluss subcutaneous.Recording electrode inserts in cranium
Top center position, reference electrode is placed in picking up the ears mastoid location, and ground wire electrode inserts in subcutaneous to mastoid process of picking up the ears, and is subsequently placed in electric screen
Cover in ferrum case.Application Smart-EP Manual Version 3.97 test system (Zhi Ting company of the U.S.).Using tone burst thorn
Swash (2,4,8,16,32kHz), 1.6ms, rise/fall time be 2 cycles, plateau be 1 cycle, from Blackman
Window envelope control sidelobe energy.Positive and negative alternately polarity stimulates, electrode resistance<5 Ω, stimulus frequency is 21.2/s, observes time-histories
12.8ms, filtering bandwidth 100～500Hz, are superimposed 512 times, start to stimulate with 80dBSPL, 10dB successively decreases, close to threshold value when with
5dB successively decreases, and is repeated 2 times.When measuring 16,32kHz, with high frequency earphone to sound；Measure 2,4,8kHz when, with ER3 earphone to sound.
C-ABR detects the threshold of audibility：Stimulus signal is short sound 100ms, stimulus frequency 11.1/s, filtering bandwidth 100～3000Hz,
Superposition 512 times, observes time-histories 12.8ms, adopts TDH-49P earphone to sound during mensure.Remaining is tested with Tb-ABR.
Statistical procedures：Data is represented using means standard deviation, using SPSS 11.5 software kit, result is counted
Credit is analysed, with P<0.05 is that difference is statistically significant.
Testing result is as shown in table 5：
The protective effect to noise induced hearing loss for table 5. nutrient of the present invention
Continued 5
In table 5,0 group is experimental comparison group, and 1 group is 1 group of nutrient, and 2 groups is 2 groups of nutrient, and 3 groups is 3 groups of nutrient；With
Compare for 0 group, * P<0.05；Compared with 1 group, #P<0.05；， ＆P compared with 2 groups<0.05.
Result shows, persistently gives the threshold of audibility that nutrient of the present invention can significantly improve caused by noise exposure and pure tone audiometry
Abnormal rising, has the effect of clear and definite noise immunity hearing loss, wherein, (i.e. the optimization of the present invention is joined with nutrient 3 especially
Side) protected effect optimal, it is to the protective effect of the temporary hearing threshold shift of caused by noise exposure up to 19dB.
Although above in conjunction with subordinate list, invention has been described, the invention is not limited in above-mentioned being embodied as
Mode, above-mentioned specific embodiment is only schematically, rather than restricted, and those of ordinary skill in the art is at this
Under the enlightenment of invention, without deviating from the spirit of the invention, many variations can also be made, these belong to the present invention's
Within protection.
Claims (8)
1. a kind of nutrient with noise immunity hearing loss is it is characterised in that be made up of following raw materials by weight：N-
Acetyl-L-Cysteine 600-1000 part, vitamin A 1-4 part, vitamin B1 1-5 part, vitamin B2 1-5 part, vitamin
B6 1-10 part, vitamin B12 0.01-0.05 part, vitamin C 60-1000 part, Vitamin E 15-300 in terms of alpha-tocopherol
Part, magnesium 50-400 part and food acceptable adjuvant 79-3175 part.
2. the nutrient with noise immunity hearing loss according to claim 1 it is characterised in that described N- acetyl-
900 parts of L-Cysteine, 3 parts of vitamin A, 2.5 parts of vitamin B1,2.5 parts of vitamin B2,2 parts of vitamin B6, vitamin
0.01 part of B12,500 parts of vitamin C, Vitamin E in terms of alpha-tocopherol 270 parts, 300 parts of magnesium and the acceptable adjuvant of food
225 parts, wherein, the acceptable adjuvant of described food includes：100 parts of Lactose, 80 parts of Microcrystalline Cellulose, 40 parts of carboxymethyl starch sodium
With 5 parts of magnesium stearate.
3. the nutrient with noise immunity hearing loss according to claim 1 it is characterised in that described N- acetyl-
900 parts of L-Cysteine, 3 parts of vitamin A, 2.5 parts of vitamin B1,2.5 parts of vitamin B2,2 parts of vitamin B6, vitamin
0.01 part of B12,500 parts of vitamin C, Vitamin E in terms of alpha-tocopherol 270 parts, 300 parts of magnesium and the acceptable adjuvant of food
79 parts, wherein, the acceptable adjuvant of described food includes：15 parts of Hypromellose, 15 parts of Hypromellose, carboxymethyl form sediment
45 parts of powder sodium and 4 parts of magnesium stearate.
4. the nutrient with noise immunity hearing loss according to claim 1 it is characterised in that described N- acetyl-
900 parts of L-Cysteine, 20 parts of Vitamin A Acetate Powder, 2.5 parts of vitamin B1,2.5 parts of vitamin B2, vitamin B6 2
Part, 0.01 part of vitamin B12,500 parts of vitamin C, 540 parts of Vitamin E acetate, 5200 parts of magnesium gluconate and food can
3175 parts of the adjuvant accepting, wherein, the acceptable adjuvant of described food includes：1000 parts of citric acid, 500 parts of malic acid, carbonic acid
1400 parts of hydrogen sodium, 35 parts of aspartame, 60 parts of orange flavor, 60 parts of sodium chloride and PEG6000120 part.
5. according to the described nutrient with noise immunity hearing loss arbitrary in Claims 1-4 it is characterised in that institute
The standard having raw material is all using medicinal standard or food sanitation standard.
6. the nutrient with noise immunity hearing loss according to claim 1 is it is characterised in that described nutrient
Dosage form is any one of powder, tablet, granule, capsule and oral fluid agent.
7. the nutrient with noise immunity hearing loss according to claim 4 is it is characterised in that described nutrient
Dosage form is one of hard capsule, soft capsule, coated tablet, Film coated tablets, Special-shaped sheet, chewable tablet, effervescent tablet, dispersible tablet, syrup.
8. the nutrient with noise immunity hearing loss according to claim 1 is it is characterised in that described nutrient is made
Add in food for food additive and make functional food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510137493.8A CN104664407B (en) | 2015-03-26 | 2015-03-26 | A kind of nutrient with noise immunity hearing loss |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510137493.8A CN104664407B (en) | 2015-03-26 | 2015-03-26 | A kind of nutrient with noise immunity hearing loss |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CN104664407A CN104664407A (en) | 2015-06-03 |
| CN104664407A8 CN104664407A8 (en) | 2017-02-15 |
| CN104664407B true CN104664407B (en) | 2017-03-01 |
Family
ID=53300412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510137493.8A Active CN104664407B (en) | 2015-03-26 | 2015-03-26 | A kind of nutrient with noise immunity hearing loss |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104664407B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022162036A1 (en) * | 2021-01-27 | 2022-08-04 | Société des Produits Nestlé S.A. | Compositions and methods for use in increasing motivational performance |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105192512A (en) * | 2015-10-14 | 2015-12-30 | 北京康比特体育科技股份有限公司 | Composition for improving antioxidant capacity of human bodies in movement |
| CN108309964B (en) * | 2018-04-04 | 2020-06-30 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Application of metformin in the preparation of noise-induced hearing loss prevention and treatment products |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391913A (en) * | 2001-06-14 | 2003-01-22 | 大连轻工业学院 | Oral liquid against noise and its preparing method |
| CN102512682A (en) * | 2012-01-12 | 2012-06-27 | 王玉丰 | Medicinal composition for treating noise-induced hearing impairment and application of medicinal composition |
-
2015
- 2015-03-26 CN CN201510137493.8A patent/CN104664407B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391913A (en) * | 2001-06-14 | 2003-01-22 | 大连轻工业学院 | Oral liquid against noise and its preparing method |
| CN102512682A (en) * | 2012-01-12 | 2012-06-27 | 王玉丰 | Medicinal composition for treating noise-induced hearing impairment and application of medicinal composition |
Non-Patent Citations (3)
| Title |
|---|
| N－乙酰半胱氨酸对短期噪声暴露引起豚鼠听力损伤的保护作用;戴子渊等;《药学服务与研究》;20140430;第14卷(第2期);第107－110页，参见摘要 * |
| 哪些食物有益听力;未知;《西部财会》;20050131(第1期);第63页 * |
| 噪声性听觉损伤防治的研究进展;徐灵活等;《海军医学杂志》;20061231;第27卷(第45期);第360－363页 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022162036A1 (en) * | 2021-01-27 | 2022-08-04 | Société des Produits Nestlé S.A. | Compositions and methods for use in increasing motivational performance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104664407A (en) | 2015-06-03 |
| CN104664407A8 (en) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7951845B2 (en) | Composition and method of treating hearing loss | |
| Campbell et al. | Prevention of noise-and drug-induced hearing loss with D-methionine | |
| US8338397B2 (en) | Composition and method of treating side effects from antibiotic treatment | |
| Spratley et al. | Topical ascorbic acid reduces myringosclerosis in perforated tympanic membranes a study in the rat | |
| CN104664407B (en) | A kind of nutrient with noise immunity hearing loss | |
| US20100305075A1 (en) | Composition and method of treating hearing loss | |
| KR20180089207A (en) | Pharmaceutical composition or health functional food for preventing or treating of sensorineural hearing loss comprising eisenia bicyclis extract as an active ingredient | |
| Fetoni et al. | The protective role of tiopronin in cisplatin ototoxicity in Wistar rats | |
| CA2543870A1 (en) | Therapeutic use of methionine for the treatment or prevention of mucositis | |
| US9770433B2 (en) | Composition and method for treating tinnitus | |
| US20130078320A1 (en) | Composition for treating hearing loss | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| Uzun et al. | Garlic-supplemented diet attenuates gentamicin-induced ototoxicity: an experimental study | |
| JP5407079B2 (en) | New use of 3,3'-diindolylmethane | |
| CN111936129A (en) | Natural combination products and methods for regulating the renal and excretory systems | |
| WO2011147252A1 (en) | Compound preparation and its uses for prevention and treatment of hearing impairment | |
| CN108309964A (en) | Application of the melbine in preparing noise induced hearing loss prevention product | |
| Egbuonu et al. | Influence of Chrysophyllum albidum seed endosperm extract on hematologic, hepatic, nephrotic and histologic alterations in monosodium glutamate-compromised rats | |
| CN111138438B (en) | Pyrazolopyrimidinone compound and application of composition thereof in prevention and treatment of military noise hearing loss | |
| US9919008B2 (en) | Method for treating age-related hearing loss (ARHL) | |
| EP3071197B1 (en) | Food for special medical purposes or food supplement formulation for treating hearing disturbances | |
| JPWO2009044548A1 (en) | Anti-diarrhea composition, contents thereof and method for preventing diarrhea | |
| Civan et al. | The effects of ginseng and exercise applications in sedentary individuals in women athletes on lipid hydroperoxide and nitric oxide | |
| JP2008031110A (en) | Pain prevention or alleviation agent | |
| RU2005134602A (en) | HEALING AND HEALTHY BIOLOGICALLY ACTIVE ADDITIVE "MUDRASANA" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CI01 | Publication of corrected invention patent application |
Correction item: Applicant Correct: Inst. of Hygiolgy & Enviromental Medicine, Academy of Military Medicine, CPLA. False: Hygiene environmental medicine research institute of Academy of Military Medicine, PLA Number: 22 Volume: 31 |
|
| CI02 | Correction of invention patent application |
Correction item: Applicant Correct: Inst. of Hygiolgy & Enviromental Medicine, Academy of Military Medicine, CPLA. False: Hygiene environmental medicine research institute of Academy of Military Medicine, PLA Number: 22 Page: The title page Volume: 31 |
|
| ERR | Gazette correction | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |